New treatment for inoperable pancreatic cancer form offers hope. Here's what Optune Pax does.

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.
The American Journal of Managed Care

FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer

FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...
Zacks Investment Research on MSN

Novocure's Optune Lua gets Japan reimbursement for NSCLC treatment

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...
Medical Xpress

FDA approves noninvasive Optune Pax device for advanced pancreatic cancer

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...
Targeted Oncology

Oncology Frontiers: Recapping a Milestone February for FDA Approvals

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...